51 Quotes by Tim Anderson

The quarter was good in that they didn't have anything negative at a time when a lot of people are wary about earnings,

The proof of the pudding will be what are the benefits at the checkpoint. Will you be able to move through faster? If so, I think this will be a very well-received program.

The real pivotal one will be Claritin, ... You could see some very good growth there.

We just had to bounce back strong. This was a statement our team had to make.

The private sector believes they can make money at this, and we hope they do.

We expect the company to put up a good show, give guidance that is ahead of consensus and not have any significant negative surprises.

The stock has reached our target of $44 and we have difficulty raising it much from here.

Schering will be coming out with a second generation (Claritin) drug in the next few months, so it depends how many people they convert (to the new drug), ... They could be in Merck's shoes a few quarters from now, but I don't think they have the visibility to say.

Anything that moves it forward is a good thing, and this looks like it's moving forward.